SUCCINCT: An open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with Sunitinib as first-line treatment for patients with advanced urothelial carcinoma

SUCCINCT: An open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with Sunitinib as first-line treatment for patients with advanced urothelial carcinoma

Gemcitabine and cisplatin chemotherapy (GC regimen) represents a standard treatment for advanced urothelial carcinoma. We performed an open-label, single-arm, non-randomised, phase 2 trial evaluating the addition of sunitinib to standard GC chemotherapy (SGC regimen). Overall, 63 treatment-naïve pa...

Full description

Bibliographic Details
Main Authors: Geldart, Thomas (Author), Chester, John (Author), Casbard, Angela (Author), Crabb, Simon (Author), Elliott, Tony (Author), Protheroe, Andrew (Author), Huddart, Robert A. (Author), Mead, Graham (Author), Barber, Jim (Author), Jones, Robert J. (Author), Smith, Joanna (Author), Cowles, Robert (Author), Evans, Jessica (Author), Griffiths, Gareth (Author)
Format: Article
Language:English
Published: 2015-04.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items